22 Recruiting Studies Using Retifanlimab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Retifanlimab
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
View Study & Checklist ➔Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
📍 Los Angeles General Medical Center — Los Angeles, California
Advanced Malignant Skin Neoplasm
View Study & Checklist ➔Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
📍 Washington University School of Medicine — St Louis, Missouri
Unmethylated Glioblastoma
View Study & Checklist ➔Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
📍 Mayo Clinic Rochester — Scottsdale, Arizona
Head and Neck Cancer
View Study & Checklist ➔Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
📍 Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist ➔Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
📍 Massachusetts General Hospital — Boston, Massachusetts
Pancreatic Cancer Metastatic
View Study & Checklist ➔All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
📍 University of Pennsylvania — Philadelphia, Pennsylvania
Glioma
View Study & Checklist ➔Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Anaplastic Oligodendroglioma
View Study & Checklist ➔9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Pancreatic Adenocarcinoma
View Study & Checklist ➔A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
📍 Johns Hopkins — Baltimore, Maryland
BRAF V600E Mutation
View Study & Checklist ➔Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
Recurrent Glioblastoma
View Study & Checklist ➔Retifanlimab and Ruxolitinib In Solid Malignancies
📍 University of California, San Diego Moores Cancer Center — La Jolla, California
Non Small Cell Lung Carcinoma
View Study & Checklist ➔Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
📍 UCLA Medical Center — Los Angeles, California
Neurofibromatosis Type 2
View Study & Checklist ➔Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
📍 Johns Hopkins Medical Institution — Baltimore, Maryland
Glioblastoma Multiforme
View Study & Checklist ➔Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Soft Tissue Sarcoma
View Study & Checklist ➔A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
Breast Cancer
View Study & Checklist ➔Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
📍 OHSU Knight Cancer Institute — Portland, Oregon
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
📍 Mayo Clinic Hospital — Phoenix, Arizona
Solid Tumors
View Study & Checklist ➔Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
📍 Mayo Clinic-Comprehensive Cancer Center-Breast Clinic — Phoenix, Arizona
Breast Cancer
View Study & Checklist ➔Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Metastatic Colorectal Cancer
View Study & Checklist ➔ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
📍 University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
Anal Cancer
View Study & Checklist ➔